Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab and Nab-Paclitaxel in Primary Breast Cancer
NCT02682693Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of denosumab in breast cancer (4 arms), sponsored by GBG Forschungs. Primary endpoints: Pathological Complete Response (ypT0 ypN0) at 24 weeks and Pathological Complete Response by Nab-Paclitaxel Schedule at 12 weeks. Started Feb 2017; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02682693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02682693.